A Randomized Phase 2 Study of Rebeccamycin Analog in Advanced Breast Cancer.
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Becatecarin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Jan 2013 Actual end date May 2006 added as reported by ClinicalTrials.gov.
- 31 Jan 2013 Actual initiation date changed from Jun 2000 to Mar 2000 as reported by ClinicalTrials.gov.
- 25 Oct 2007 Status changed from in progress to completed.